

# VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100**

## Overview

<b>2024/04/26 17:35:33</b>	
<b>Price</b>	<b>372.55 EUR</b>
<b>Difference</b>	<span style="color: green;">▲</span> <b>1.20% (4.40)</b>

<b>General attributes</b>	
<b>ISIN</b>	US92532F1003
<b>Symbol</b>	VRTX
<b>Exchange</b>	Xetra
<b>Currency</b>	EUR
<b>Sector</b>	Chemical / Pharmaceutical / Health
<b>Security type</b>	Stock
<b>Market cap (m)</b>	95,767 EUR
<b>Benchmark</b>	S&P 500

<b>Market data</b>	
<b>Bid (Bid size)</b>	-
<b>Ask (Ask size)</b>	-
<b>Open</b>	369.00 EUR
<b>High</b>	372.55 EUR
<b>Low</b>	366.90 EUR
<b>Close (prev. day)</b>	368.15 EUR
<b>VWAP</b>	367.72065 EUR
<b>Volume (pcs)</b>	46
<b>Trading volume</b>	16,915.15
<b>Number of trades</b>	9
<b>Last size</b>	1

<b>Futures and Options</b>	
<b>Related Futures</b>	-
<b>Related Options</b>	-

<b>PDF Downloads</b>	
Company report: VERTEX PHARMACEUTICALS INC.	<a href="#"></a>



Information about previous performance does not guarantee future performance.  
**Source:** FactSet

### Recent research

on instrument	on sector	on market	
Date		Headline	Download
2024/04/26		Global Equity Ratings	<a href="#"></a>
2024/04/03		Global Equity Ratings	<a href="#"></a>
2024/03/13		Global Equity Ratings	<a href="#"></a>
2024/02/22		Global Equity Ratings	<a href="#"></a>
2024/02/14		Global Equity Ratings	<a href="#"></a>

## Details

2024/04/26 17:35:33

**Price**

372.55 EUR

**Difference** ▲ 1.20% (4.40)

**General attributes**

ISIN	US92532F1003
Symbol	VRTX
Exchange	Xetra
Currency	EUR
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	95,767 EUR
Benchmark	S&P 500

**Market data**

Bid (Bid size)	-
Ask (Ask size)	-
Open	369.00 EUR
High	372.55 EUR
Low	366.90 EUR
Close (prev. day)	368.15 EUR
VWAP	367.72065 EUR
Volume (pcs)	46
Trading volume	16,915.15
Number of trades	9
Last size	1

**Performance and Risk**

	6m	1Y	3Y
Perf (%)	+6.37%	+20.76%	+104.53%
Perf (abs.)	+22.05	+63.30	+188.15
Beta	0.76	0.71	0.60
Volatility	25.35	22.39	26.61

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

**Price data**

Ø price 5 days   Ø volume 5 days (pcs.)	373.70 EUR (129)
Ø price 30 days   Ø volume 30 days (pcs.)	376.99 EUR (175)
Ø price 100 days   Ø volume 100 days (pcs.)	379.45 EUR (170)
Ø price 250 days   Ø volume 250 days (pcs.)	346.69 EUR (105)
YTD High   date	420.00 EUR (2024/01/31)
YTD Low   date	353.40 EUR (2024/04/11)
52 Weeks High   date	420.00 EUR (2024/01/31)
52 Weeks Low   date	286.05 EUR (2023/04/26)

**All listings for VERTEX PHARMACEUTICALS INC.**

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/04/26	17:35	372.55 EUR	0.02	9
Vienna Stock Exchange	2024/04/26	17:32	372.90 EUR	0.00	2
Tradegate	2024/04/26	17:46	373.40 EUR	0.04	9
Stuttgart	2024/04/26	08:01	370.60 EUR	0.00	1
Nasdaq	2024/	17:55	398.665 USD	74.29	7,653

	04/26					
Munich	2024/ 04/26	08:00	370.50 EUR	0.00		1
London Stock Exchange	2024/ 04/26	15:54	395.17 USD	0.01		12
Hanover	2024/ 04/26	08:05	370.75 EUR	0.00		1
Hamburg	2024/ 04/26	08:00	370.75 EUR	0.00		1
Frankfurt	2024/ 04/26	08:01	371.80 EUR	0.00		1
Euronext Milan MTF Trading After Hours	2024/ 02/28	19:24	393.60 EUR	0.00		1
Euronext Milan MTF Global Equity Market	2024/ 04/26	17:44	371.90 EUR	0.00		3
Duesseldorf	2024/ 04/26	16:30	371.75 EUR	0.00		4
Berlin	2024/ 04/26	08:08	370.80 EUR	0.00		1

## Company profile

### Company Logo



### Contact Details

VERTEX PHARMACEUTICALS INC.

--

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: [mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

### PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC.



### Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

### Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Michel Lagarde	Member of Board of Directors
Nancy Thornberry	Member of Board of Directors
Suketu Upadhyay	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Reshma Kewalramani	Chairman of Managing Board
David Altshuler	Member of Executive Committee
Amit K. Sachdev	Member of Executive Committee
Bastiano Sanna	Member of Executive Committee
Carmen Bozic	Member of Executive Committee
Charles F. Wagner	Member of Executive Committee
E. Morrey Atkinson	Member of Executive Committee
Jonathan Biller	Member of Executive Committee
Nia Tatsis	Member of Executive Committee
Stuart A. Arbuckle	Member of Executive Committee

